Gilead Sciences has | Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was ...

HAYWARD, Calif., August 06, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Key Points GAAP revenue far exceeded expectations, reaching $160 million in Q2 2025, driven by a one-time $143 million GAAP catch-up related to program changes with Gilead. GAAP earnings per share ...

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers ...

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech's chief medical officer Bill Grossman to a new role as its head of oncology ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination ...

Gilead Sciences and Arcus Biosciences are conducting a Phase 3 clinical study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With ...

HAYWARD, Calif.-- (BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...